Oren Cohen, MD, is President of Clinical Pharmacology and Chief Medical Officer, partnering with biopharmaceutical companies to optimize early clinical development through excellence in study design and execution. He has served in this position since Fortrea’s launch as an independent company in July 2023 following its spinoff from Labcorp.
Following a decade of translational research at the U.S. National Institute of Allergy and Infectious Diseases under the mentorship of Anthony Fauci, MD, Oren has more than 20 years of experience in various medical and scientific executive leadership roles in the pharmaceutical industry. Most recently, Oren served as Chief Medical Officer and head of Clinical Pharmacology Services at Labcorp Drug Development since 2017. Prior to Labcorp, he was Chief Medical Officer at Viamet Pharmaceuticals, where he worked closely with clinical investigators and key opinion leaders to formulate and execute clinical development programs across a portfolio, developing and executing strategy and protocol designs. Previously, he held several senior medical and operational leadership positions at Quintiles, now part of IQVIA.
Oren received his MD from Duke University and served his internship and residency at The New York Hospital, Cornell Medical Center in New York City. He completed his infectious diseases fellowship at the National Institute of Allergy and Infectious Diseases (NIAID) and stayed on to become an investigator in the Laboratory of Immunoregulation. Oren is also Consulting Professor of Medicine at Duke University Medical Center, a member of the Board of Visitors for Duke University School of Medicine and a Fellow of the Infectious Diseases Society of America. His research has been published in journals including The New England Journal of Medicine, Science, Proceedings of the National Academy of Sciences, Nature Medicine and the Journal of Clinical Investigation.
Jordi is a hands-on senior executive, entrepreneurial-minded, with solid experience in Computer Software, Advanced Analytics and AI, Digital Transformation, Management and Strategy Consulting, having worked in small to mid-size companies and VC-baked startups in the B2B space with strong focus in Life Sciences & Healthcare industries. I love business growth stage dynamics.
Giuseppe Bene comes from a technical background in Aerospace Research & Technological Development towards Avio Group (4 years) and Train Maintenance Engineering in Trenitalia (10 years). He is specialized in statistical analyses and prognostic algorithm development for mechanical systems. He is involved in Railways Vehicle Authorization processes towards the Railways National Safety Agency in Italy (ANSFISA) since 2021.
Carsten is a strategy and change leader with over 22yrs of cross-functional and international responsibilities covering agile transformation, strategy, finance and M&A advisory. He is currently Agile Lead Sales Channels, Private Bank Transformation, Deutsche Bank
Previously he performed variety of management roles at DB over the last 9 years in the International Private Bank, Wealth Management and Group including roles as Member of Regional Councils & Operating Committees as Head of Strategy / CFO or when driving company-wide transformation.
Earlier in his career, he worked 13 years with KPMG’s Strategy & Corporate Finance M&A teams in London, Tokyo and Frankfurt.
Celeste Leverton is an award-winning individual, experienced in and passionate about sustainability strategy creation, client engagement and ESG Investing. She co-led Coutts through the B Corp certification process, making the company the 1st UK HQ’d Private Bank. As a result of this pioneering work, she’s been able to support over 60 clients and 10 suppliers create and implement their own frameworks and Sustainable strategies. More recently, Celeste moved into Coutts’ Responsible Investing team as a manager
As Development Environmental Sustainability Lead of Novartis, Jürgen is responsible for Sustainable Product & Process Design and the set-up and execution of greener clinical trials. He contributes within the UK-based Sustainable Healthcare Coalition to the industries’ low carbon clinical trial workstream. He is a member of the Novartis Environmental Sustainability Strategy Leadership Team of Novartis. Novartis was awarded in November 2023 with the prestigious “Terra Carta Seal” from the Sustainable Markets Initiative (SMI) based on the Greener Clinical Trial program led by Jürgen.
Jürgen has been passionate about the topic of Environmental Sustainability since >30 years. Prior joining Novartis in 2011, he was the CFO of the NGO “Solar Energy Foundation”, supporting the roll-out of solar energy in rural East Africa. Until 2020 he was the Finance Head of the Novartis Global Clinical Supply unit, during which he was awarded with the “Better World Award for Environmental Sustainability” for the decarbonization of clinical trials.
Mattia was born in Italy and he has an BSc in Biotechnology and an MSc in Industrial Biotechnology.
He has been working in pharmaceutical companies for about 12 years, initially as Chemical Analyst, then as GMP compliance specialist and finally, during the last 7 years, in Clinical Supplies.
Mattia has worked for Chiesi Farmaceutici in Italy, Argenx in Belgium, Debiopharm and Incyte in Switzerland. He is currently based in Switzerland and working for Incyte within the Global Clinical Supplies group.
